Pediatric Cancer Clinical Trial
— RePlayOfficial title:
Rehabilitation Including Structured Active Play for Preschoolers With Cancer.
Treatment for childhood cancer causes treatment-related acute adverse events such as muscle weakness and physical incompetence. With long admissions, isolation, and long-term bed rest, this means reduced physical activity and, ultimately, gross motor functioning development is affected. Furthermore, the children participate less in sport and leisure activities, inhibiting social skills, and the children feel isolated from peers. The above makes it difficult for children to return to everyday activities. Physical activity in the form of play and movement activities is essential for preschool children's gross motor, social, and personal development- a development where parents play a crucial role. Replay is a randomized controlled trial that will include 84 children with cancer aged 1-5 years at the University Hospital Copenhagen, Rigshospitalet. The children are included at the treatment initiation and are randomized to either the intervention group or the control group. The intervention consists of six months of daily structured play-based physical activity, including daily parent administered play and movement and three weekly group-based play and movement sessions at the hospital during admissions. Gross motor and physical function is measured with 1) Peabody Developmental Motor Scales, Second Edition (PDMS-2), Pediatric Evaluation of Disability Inventory (PEDI), Handgrip strength, and a six-minute walk test. The assessment time points are baseline (initiated timepoint), 3- and 6 months (endpoint) after initiated treatment. The intervention group will be observed and invited to participate in qualitative interviews. The control group will receive usual care and specific physiotherapy if needed.
Status | Recruiting |
Enrollment | 84 |
Est. completion date | December 30, 2025 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Months to 5 Years |
Eligibility | Inclusion Criteria: - Children diagnosed with cancer or benign disorders and are being treated with chemotherapy and/or radiation and are admitted to the Department of Pediatric Hematology/Oncology at University Hospital Copenhagen, Rigshospitalet. - Children at the age of 1-5,9 years at diagnosis. - Children whose parents can communicate in Danish. Exclusion Criteria: - Children with mental disabilities that complicates the ability to follow instructions. |
Country | Name | City | State |
---|---|---|---|
Denmark | Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark | Danish Cancer Society, Danish Child Cancer Foundation, University of Copenhagen |
Denmark,
Almqvist L, Hellnas P, Stefansson M, Granlund M. 'I can play!' young children's perceptions of health. Pediatr Rehabil. 2006 Jul-Sep;9(3):275-84. doi: 10.1080/13638490500521303. — View Citation
Bellows LL, Davies PL, Anderson J, Kennedy C. Effectiveness of a physical activity intervention for Head Start preschoolers: a randomized intervention study. Am J Occup Ther. 2013 Jan-Feb;67(1):28-36. doi: 10.5014/ajot.2013.005777. — View Citation
Bjork M, Nordstrom B, Hallstrom I. Needs of young children with cancer during their initial hospitalization: an observational study. J Pediatr Oncol Nurs. 2006 Jul-Aug;23(4):210-9. doi: 10.1177/1043454206289737. — View Citation
Bjorklund DF, Brown RD. Physical play and cognitive development: integrating activity, cognition, and education. Child Dev. 1998 Jun;69(3):604-6. — View Citation
Braam KI, van der Torre P, Takken T, Veening MA, van Dulmen-den Broeder E, Kaspers GJ. Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2016 Mar 31;3(3):CD008796. doi: 10.1002/14651858.CD008796.pub3. — View Citation
Darcy L, Enskar K, Bjork M. Young children's experiences of living an everyday life with cancer - A three year interview study. Eur J Oncol Nurs. 2019 Apr;39:1-9. doi: 10.1016/j.ejon.2018.12.007. Epub 2018 Dec 23. — View Citation
Enright PL. The six-minute walk test. Respir Care. 2003 Aug;48(8):783-5. — View Citation
Faigenbaum AD, Rebullido TR, MacDonald JP. Pediatric Inactivity Triad: A Risky PIT. Curr Sports Med Rep. 2018 Feb;17(2):45-47. doi: 10.1249/JSR.0000000000000450. No abstract available. — View Citation
Frederiksen LE, Mader L, Feychting M, Mogensen H, Madanat-Harjuoja L, Malila N, Tolkkinen A, Hasle H, Winther JF, Erdmann F. Surviving childhood cancer: a systematic review of studies on risk and determinants of adverse socioeconomic outcomes. Int J Cancer. 2019 Apr 15;144(8):1796-1823. doi: 10.1002/ijc.31789. Epub 2018 Oct 30. — View Citation
Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA; EUROCARE Working Group. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009 Apr;45(6):992-1005. doi: 10.1016/j.ejca.2008.11.042. Epub 2009 Feb 21. — View Citation
Gibson F, Aldiss S, Horstman M, Kumpunen S, Richardson A. Children and young people's experiences of cancer care: a qualitative research study using participatory methods. Int J Nurs Stud. 2010 Nov;47(11):1397-407. doi: 10.1016/j.ijnurstu.2010.03.019. Epub 2010 Apr 28. — View Citation
Gibson TM, Mostoufi-Moab S, Stratton KL, Leisenring WM, Barnea D, Chow EJ, Donaldson SS, Howell RM, Hudson MM, Mahajan A, Nathan PC, Ness KK, Sklar CA, Tonorezos ES, Weldon CB, Wells EM, Yasui Y, Armstrong GT, Robison LL, Oeffinger KC. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2018 Dec;19(12):1590-1601. doi: 10.1016/S1470-2045(18)30537-0. Epub 2018 Nov 8. Erratum In: Lancet Oncol. 2019 Jan;20(1):e10. — View Citation
Hager-Ross C, Rosblad B. Norms for grip strength in children aged 4-16 years. Acta Paediatr. 2002;91(6):617-25. doi: 10.1080/080352502760068990. — View Citation
Hansson H, Hallstrom I, Kjaergaard H, Johansen C, Schmiegelow K. Hospital-based home care for children with cancer. Pediatr Blood Cancer. 2011 Sep;57(3):369-77. doi: 10.1002/pbc.23047. Epub 2011 May 18. — View Citation
Hansson H, Kjaergaard H, Schmiegelow K, Hallstrom I. Hospital-based home care for children with cancer: a qualitative exploration of family members' experiences in Denmark. Eur J Cancer Care (Engl). 2012 Jan;21(1):59-66. doi: 10.1111/j.1365-2354.2011.01280.x. Epub 2011 Aug 18. — View Citation
Hartman A, te Winkel ML, van Beek RD, de Muinck Keizer-Schrama SM, Kemper HC, Hop WC, van den Heuvel-Eibrink MM, Pieters R. A randomized trial investigating an exercise program to prevent reduction of bone mineral density and impairment of motor performance during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009 Jul;53(1):64-71. doi: 10.1002/pbc.21942. — View Citation
Hildenbrand AK, Clawson KJ, Alderfer MA, Marsac ML. Coping with pediatric cancer: strategies employed by children and their parents to manage cancer-related stressors during treatment. J Pediatr Oncol Nurs. 2011 Nov-Dec;28(6):344-54. doi: 10.1177/1043454211430823. — View Citation
Morales JS, Santana-Sosa E, Santos-Lozano A, Bano-Rodrigo A, Valenzuela PL, Rincon-Castanedo C, Fernandez-Moreno D, Gonzalez Vicent M, Perez-Somarriba M, Madero L, Lassaletta A, Fiuza-Luces C, Lucia A. Inhospital exercise benefits in childhood cancer: A prospective cohort study. Scand J Med Sci Sports. 2020 Jan;30(1):126-134. doi: 10.1111/sms.13545. Epub 2019 Oct 6. — View Citation
Ness KK, Baker KS, Dengel DR, Youngren N, Sibley S, Mertens AC, Gurney JG. Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007 Dec;49(7):975-81. doi: 10.1002/pbc.21091. — View Citation
Ness KK, Hudson MM, Pui CH, Green DM, Krull KR, Huang TT, Robison LL, Morris EB. Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer. 2012 Feb 1;118(3):828-38. doi: 10.1002/cncr.26337. Epub 2011 Jul 15. — View Citation
Ness KK, Kaste SC, Zhu L, Pui CH, Jeha S, Nathan PC, Inaba H, Wasilewski-Masker K, Shah D, Wells RJ, Karlage RE, Robison LL, Cox CL. Skeletal, neuromuscular and fitness impairments among children with newly diagnosed acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Apr;56(4):1004-11. doi: 10.3109/10428194.2014.944519. Epub 2014 Aug 20. — View Citation
Neumann S, Kwisda S, Krettek C, Gaulke R. Comparison of the Grip Strength Using the Martin-Vigorimeter and the JAMAR-Dynamometer: Establishment of Normal Values. In Vivo. 2017 Sep-Oct;31(5):917-924. doi: 10.21873/invivo.11147. — View Citation
Nielsen MKF, Christensen JF, Frandsen TL, Thorsteinsson T, Andersen LB, Christensen KB, Nersting J, Faber M, Schmiegelow K, Larsen HB. Testing physical function in children undergoing intense cancer treatment-a RESPECT feasibility study. Pediatr Blood Cancer. 2018 Aug;65(8):e27100. doi: 10.1002/pbc.27100. Epub 2018 May 9. — View Citation
Robertson A, Deitz J. A description of grip strength in preschool children. Am J Occup Ther. 1988 Oct;42(10):647-52. doi: 10.5014/ajot.42.10.647. — View Citation
Schroder H, Rechnitzer C, Wehner PS, Rosthoj S, Moller JK, Lausen B, Petersen G, Norgaard M. Danish Childhood Cancer Registry. Clin Epidemiol. 2016 Oct 25;8:461-464. doi: 10.2147/CLEP.S99508. eCollection 2016. — View Citation
Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010 May 20;28(15):2625-34. doi: 10.1200/JCO.2009.27.0421. Epub 2010 Apr 19. — View Citation
Stahlhut M, Christensen J, Aadahl M. Applicability and intrarespondent reliability of the pediatric evaluation of disability inventory in a random Danish sample. Pediatr Phys Ther. 2010 Summer;22(2):161-9. doi: 10.1097/PEP.0b013e3181dbf965. — View Citation
Thorsteinsson T, Larsen HB, Schmiegelow K, Thing LF, Krustrup P, Pedersen MT, Christensen KB, Mogensen PR, Helms AS, Andersen LB. Cardiorespiratory fitness and physical function in children with cancer from diagnosis throughout treatment. BMJ Open Sport Exerc Med. 2017 May 12;3(1):e000179. doi: 10.1136/bmjsem-2016-000179. eCollection 2017. — View Citation
Thorsteinsson T, Schmiegelow K, Thing LF, Andersen LB, Helms AS, Ingersgaard MV, Lindgren LH, Larsen HB. Classmates motivate childhood cancer patients to participate in physical activity during treatment: A qualitative study. Eur J Cancer Care (Engl). 2019 Sep;28(5):e13121. doi: 10.1111/ecc.13121. Epub 2019 Jun 18. — View Citation
van Brussel M, Takken T, van der Net J, Engelbert RH, Bierings M, Schoenmakers MA, Helders PJ. Physical function and fitness in long-term survivors of childhood leukaemia. Pediatr Rehabil. 2006 Jul-Sep;9(3):267-74. doi: 10.1080/13638490500523150. — View Citation
Vannatta K, Gerhardt CA, Wells RJ, Noll RB. Intensity of CNS treatment for pediatric cancer: prediction of social outcomes in survivors. Pediatr Blood Cancer. 2007 Oct 15;49(5):716-22. doi: 10.1002/pbc.21062. — View Citation
* Note: There are 31 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Child's health-related quality of life - Generic Core Scale | PedsQl Generic Core Scale - Proxy. Parents answer the questions about their child's helths-related quality of life. The primary endpoint is after six months. | Baseline (treatment initiation) | |
Other | Child's health-related quality of life - Generic Core Scale | PedsQl Generic Core Scale - Proxy. Parents answer the questions about their child's helths-related quality of life. The primary endpoint is after six months. | 6 months after treatment initiation (primary endpoint) | |
Other | Child's health-related quality of life - Generic Core Scale | PedsQl Generic Core Scale - Proxy. Parents answer the questions about their child's helths-related quality of life. The primary endpoint is after six months. | 12 months after treatment initiation | |
Other | Child's health-related quality of life - Generic Core Scale | PedsQl Generic Core Scale - Proxy. Parents answer the questions about their child's helths-related quality of life. The primary endpoint is after six months. | 12 months after ended treatment | |
Other | Child's health-related quality of life - Cancer | PedsQl Cancer - Proxy. Parents answer the questions about their child's helths-related quality of life. The primary endpoint is after six months. | Baseline (treatment initiation) | |
Other | Child's health-related quality of life - Cancer | PedsQl Cancer - Proxy. Parents answer the questions about their child's helths-related quality of life. The primary endpoint is after six months. | 6 months after treatment initiation (primary endpoint) | |
Other | Child's health-related quality of life - Fatigue Scale | PedsQl Fatigue Scale - Proxy. Parents answer the questions about their child's helths-related quality of life. The primary endpoint is after six months. | Baseline (treatment initiation) | |
Other | Child's health-related quality of life - Fatigue Scale | PedsQl Fatigue Scale - Proxy. Parents answer the questions about their child's helths-related quality of life. The primary endpoint is after six months. | 6 months after treatment initiation (primary endpoint) | |
Other | Child's health-related quality of life - Fatigue Scale | PedsQl Fatigue Scale - Proxy. Parents answer the questions about their child's helths-related quality of life. The primary endpoint is after six months. | 12 months after treatment initiation | |
Other | Child's health-related quality of life - Fatigue Scale | PedsQl Fatigue Scale - Proxy. Parents answer the questions about their child's helths-related quality of life. The primary endpoint is after six months. | 12 months after ended treatment | |
Other | Parents health-related quality of life | 36-Item Short Form Survey Instrument (SF 36). Parents answer questions about their own health-related quality of life. The primary endpoint is after six months. | Baseline (treatment initiation) | |
Other | Parents health-related quality of life | 36-Item Short Form Survey Instrument (SF 36). Parents answer questions about their own health-related quality of life. The primary endpoint is after six months. | 6 months after treatment initiation (primary endpoint) | |
Other | Parents health-related quality of life | 36-Item Short Form Survey Instrument (SF 36). Parents answer questions about their own health-related quality of life. The primary endpoint is after six months. | 12 months after treatment initiation | |
Other | Parents health-related quality of life | 36-Item Short Form Survey Instrument (SF 36). Parents answer questions about their own health-related quality of life. The primary endpoint is after six months. | 12 months after ended treatment | |
Other | Semi-structured interviews and observations | We expect to conduct additional studies that will include empirical data collected through semi-structured interviews and observations. The empirical data collected will be analyzed and reported in separate articles.
The children and the parents in the intervention group will be interviewed (children with no language; only the parents are interviewed). The interview is done pre-and post-intervention. Observational fieldwork will be carried out during the intervention. |
Baseline (treatment initiation) and 6 months. | |
Primary | Gross Motor Function | Gross Motor Function is measured with the gross motor function subscale of Peabody Developmental Motor Scales, Second Edition (PDMS-2). PDMS-2 gives a gross motor standard score summed by the standard score from the three gross motor domians; stationary, locomotion and object manipulation. The primary endpoint is after six months. | Baseline (treatment initiation) | |
Primary | Gross Motor Function | Gross Motor Function is measured with the gross motor function subscale of Peabody Developmental Motor Scales, Second Edition (PDMS-2). PDMS-2 gives a gross motor standard score summed by the standard score from the three gross motor domians; stationary, locomotion and object manipulation. The primary endpoint is after six months. | 3 months after treatment initiation | |
Primary | Gross Motor Function | Gross Motor Function is measured with the gross motor function subscale of Peabody Developmental Motor Scales, Second Edition (PDMS-2). PDMS-2 gives a gross motor standard score summed by the standard score from the three gross motor domians; stationary, locomotion and object manipulation. The primary endpoint is after six months. | 6 months after treatment initiation (primary endpoint) | |
Primary | Gross Motor Function | Gross Motor Function is measured with the gross motor function subscale of Peabody Developmental Motor Scales, Second Edition (PDMS-2). PDMS-2 gives a gross motor standard score summed by the standard score from the three gross motor domians; stationary, locomotion and object manipulation. The primary endpoint is after six months. | 12 months after treatment initiation | |
Primary | Gross Motor Function | Gross Motor Function is measured with the gross motor function subscale of Peabody Developmental Motor Scales, Second Edition (PDMS-2). PDMS-2 gives a gross motor standard score summed by the standard score from the three gross motor domians; stationary, locomotion and object manipulation. The primary endpoint is after six months. | 12 months after ended treatment | |
Secondary | Level of child's function in everyday life | Level of function is measured through parent structured interviews with Pediatric Evaluation of Disability Inventory (PEDI) where parents answer wuestions about their child's function in three domains self-care, mobiliy and social functioning and the child's need for help in the same three domains. The primary endpoint is after six months. | Baseline (treatment initiation) | |
Secondary | Level of child's function in everyday life | Level of function is measured through parent structured interviews with Pediatric Evaluation of Disability Inventory (PEDI) where parents answer wuestions about their child's function in three domains self-care, mobiliy and social functioning and the child's need for help in the same three domains. The primary endpoint is after six months. | 3 months after treatment initiation | |
Secondary | Level of child's function in everyday life | Level of function is measured through parent structured interviews with Pediatric Evaluation of Disability Inventory (PEDI) where parents answer wuestions about their child's function in three domains self-care, mobiliy and social functioning and the child's need for help in the same three domains. The primary endpoint is after six months. | 6 months after treatment initiation (primary endpoint) | |
Secondary | Level of child's function in everyday life | Level of function is measured through parent structured interviews with Pediatric Evaluation of Disability Inventory (PEDI) where parents answer wuestions about their child's function in three domains self-care, mobiliy and social functioning and the child's need for help in the same three domains. The primary endpoint is after six months. | 12 months after treatment initiation | |
Secondary | Level of child's function in everyday life | Level of function is measured through parent structured interviews with Pediatric Evaluation of Disability Inventory (PEDI) where parents answer wuestions about their child's function in three domains self-care, mobiliy and social functioning and the child's need for help in the same three domains. The primary endpoint is after six months. | 12 months after ended treatment | |
Secondary | Handgrip strength | Handgrip strength measured with the KLS Martin Vigorimeter. Measures in bar. The primary endpoint is after six months. | Baseline (treatment initiation) | |
Secondary | Handgrip strength | Handgrip strength measured with the KLS Martin Vigorimeter. Measures in bar. The primary endpoint is after six months. | 3 months after treatment initiation | |
Secondary | Handgrip strength | Handgrip strength measured with the KLS Martin Vigorimeter. Measures in bar. The primary endpoint is after six months. | 6 months after treatment initiation (primary endpoint) | |
Secondary | Handgrip strength | Handgrip strength measured with the KLS Martin Vigorimeter. Measures in bar. The primary endpoint is after six months. | 12 months after treatment initiation | |
Secondary | Handgrip strength | Handgrip strength measured with the KLS Martin Vigorimeter. Measures in bar. The primary endpoint is after six months. | 12 months after ended treatment | |
Secondary | Six-minute walk | Six-minute walk test is done with the measurement of total meters walk after 6 minutes. The primary endpoint is after six months. | Baseline (treatment initiation) | |
Secondary | Six-minute walk | Six-minute walk test is done with the measurement of total meters walk after 6 minutes. The primary endpoint is after six months. | 3 months after treatment initiation | |
Secondary | Six-minute walk | Six-minute walk test is done with the measurement of total meters walk after 6 minutes. The primary endpoint is after six months. | 6 months after treatment initiation (primary endpoint) | |
Secondary | Six-minute walk | Six-minute walk test is done with the measurement of total meters walk after 6 minutes. The primary endpoint is after six months. | 12 months after treatment initiation | |
Secondary | Six-minute walk | Six-minute walk test is done with the measurement of total meters walk after 6 minutes. The primary endpoint is after six months. | 12 months after ended treatment | |
Secondary | Two-minute walk | Two-minute walk test is done with the measurement of total meters walk after 2 minutes during the six-minute walk. The primary endpoint is after six months. | Baseline (treatment initiation) | |
Secondary | Two-minute walk | Two-minute walk test is done with the measurement of total meters walk after 2 minutes during the six-minute walk. The primary endpoint is after six months. | 3 months after treatment initiation | |
Secondary | Two-minute walk | Two-minute walk test is done with the measurement of total meters walk after 2 minutes during the six-minute walk. The primary endpoint is after six months. | 6 months after treatment initiation (primary endpoint) | |
Secondary | Two-minute walk | Two-minute walk test is done with the measurement of total meters walk after 2 minutes during the six-minute walk. The primary endpoint is after six months. | 12 months after treatment initiation | |
Secondary | Two-minute walk | Two-minute walk test is done with the measurement of total meters walk after 2 minutes during the six-minute walk. The primary endpoint is after six months. | 12 months after ended treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Not yet recruiting |
NCT06335745 -
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
|
N/A | |
Withdrawn |
NCT04719416 -
Relaxation Therapy in Pediatric Oncology
|
N/A | |
Completed |
NCT01645436 -
Physical Activity in Pediatric Cancer (PAPEC)
|
N/A | |
Completed |
NCT04409301 -
Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation
|
N/A | |
Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
Recruiting |
NCT05425043 -
Granulocyte Transfusions After Umbilical Cord Blood Transplant
|
N/A | |
Recruiting |
NCT05071859 -
Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study
|
||
Recruiting |
NCT03241251 -
Screening for Psychosocial Risk in Flemish Families of a Child With Cancer
|
||
Recruiting |
NCT05384288 -
Response to Influenza Vaccination in Pediatric Oncology Patients
|
||
Completed |
NCT04586491 -
The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients
|
N/A | |
Recruiting |
NCT05569512 -
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05294380 -
Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
|
||
Completed |
NCT02675166 -
Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes
|
||
Completed |
NCT02665819 -
Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility.
|
N/A | |
Not yet recruiting |
NCT05454163 -
Post-radiotherapy Rhinosinusitis in Children
|
||
Terminated |
NCT02536183 -
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01828502 -
Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer
|
Phase 2 | |
Completed |
NCT02032121 -
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors
|
N/A | |
Completed |
NCT03964259 -
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
|
Phase 1 |